Related Experiment Video
Updated: Aug 6, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Primary CNS Anaplastic Large Cell Lymphoma DUPS22 Rearranged with Gain of ALK: A Case Report and Review of the
Sindu Iska1, María Herrán1, Zackary Anderson1
1Department of Hematology and Oncology Cleveland Clinic Florida Hospital Weston Florida USA.
Abstract:
ALK-negative anaplastic large cell lymphoma (ALCL) is a rare primary central nervous system lymphoma (PCNSL). Although DUSP22 rearrangement is considered favorable in systemic ALK-negative ALCL, survival remains poor in PCNSL. We report a case of PCNSL ALK-negative ALCL with DUSP22-IRF4 rearrangement and an unusual gain of the ALK gene (2p23), complicated by transaminitis, treated with high-dose methotrexate followed by whole-brain radiation therapy, achieving durable remission exceeding 3 years. To our knowledge, this is the first reported case in the CNS setting, suggesting that DUSP22 rearrangement and ALK gain may confer a favorable prognosis.
Trial Registration:
The authors have confirmed clinical trial registration is not needed for this submission.
